Cadman E, Farber L, Berd D, Bertino J
Cancer Treat Rep. 1977 Sep;61(6):1109-16.
Thirty patients with diffuse histiocytic lymphoma (DHL) were treated with one of three regimens that included cyclophosphamide, vincristine, methotrexate with citrovorum factor rescue, and cytosine arabinoside. Twelve patients had a complete response with a predicted 50% survival of at least 76 months. The medium survival of the 11 partial responders and seven nonresponders was 18 and 6 months, respectively. The addition of methotrexate and cytosine arabinoside may have a beneficial effect in therapy for DHL. From analysis of these results, there is reason to believe that efficacy may be partially dependent on the scheduling and dose of these two drugs.
30例弥漫性组织细胞淋巴瘤（DHL）患者接受了三种治疗方案中的一种，这些方案包括环磷酰胺、长春新碱、甲氨蝶呤加亚叶酸钙解救以及阿糖胞苷。12例患者获得完全缓解，预计50%的患者至少存活76个月。11例部分缓解者和7例未缓解者的中位生存期分别为18个月和6个月。甲氨蝶呤和阿糖胞苷的加入可能对DHL治疗有有益作用。从这些结果分析来看，有理由相信疗效可能部分取决于这两种药物的给药方案和剂量。
